Business
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and
About this update from Xencor, Inc.
[{"type":"text","content":" MONROVIA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.\n\n\"Xencor’s XmAb bispecific Fc domains enable the rapid design and simplified development of Fc-containing protein structures and are being used to create new platforms, a wide range of multi-specific antibodies and engineered cytokines. At AACR, we are presenting emerging preclinical data from early-stage programs that highlight the potential of our CD28 platform and XmAb 2+1 bispecific antibody format, as well as our more advanced IL-12 cytokine, which builds off our prior work with IL-15 and IL-2,\" said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor. \"In 2021, we anticipate submitting an IND for XmAb819, our lead XmAb 2+1 CD3 bispecific antibody targeting ENPP3, and initiating a Phase 1 study in early 2022. We are also advancing through preclinical development our wholly owned lead CD28 candidate, a B7-H3 x CD28 bispecific antibody designed to be evaluated for the treatment of patients with a range of solid tumors.\"\n\nPoster presentations will be archived under \"Events & Presentations\" in the Investors section of the Company's website located at www.xencor.com.\n\nXmAb Engineered Cytokine Platform\n\n\nAbstract 1743, \"IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compared to native IL12 agents\"\n\n\nIL-12 is a potent proinflammatory cytokine produced by activated antigen-presenting cells, and it leads to proliferation of T cells and NK cells and increased cytotoxicity through high levels of interferon gamma signaling. As a potent immune stimulating protein, IL-12 can have a significant effect on shrinking tumors; however, prior clinical studies have demonstrated it to have a narrow therapeutic window, limiting potential response rates.\n\nXencor's IL-12-Fc cytokine program builds on the Company's prior work with IL-15-Fc cyto...